Incyte Corporation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Incyte Corporation sits in the top decile of US sponsors by registered trial count (#137 of 15,742 sponsors by registered trial count).
Incyte Corporation: 239 sponsored US clinical trials, 37 recruiting.
Incyte Corporation sponsors 239 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 126 completed. 50 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 7 trials.
Top-decile sponsor footprint
Incyte Corporation ranks in the top decile of sponsors by registered trial count (#137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
126 of 186 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (67.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
239 total, page 4 of 5
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT03260894
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
NCT03361865
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
NCT03358472
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
NCT03314935
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
NCT03235544
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
NCT03123588
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
NCT03257644
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
NCT03139604
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
NCT03112603
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
NCT03099304
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
NCT03144661
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
NCT03085914
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
NCT03011372
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
NCT03132324
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
NCT02998476
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
NCT02959437
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
NCT03039114
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
NCT02718300
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
NCT02924376
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
NCT02872714
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
NCT03011892
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
NCT02953704
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
NCT02953678
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02760485
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
NCT02917993
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02763319
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
NCT03059823
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
NCT02723994
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
NCT02018861
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
NCT02903914
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
NCT02752074
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT02711137
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
NCT02712905
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
NCT02646748
Study of INCB053914 in Subjects With Advanced Malignancies
NCT02587598
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
NCT02614612
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
NCT02553330
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
NCT02559492
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
NCT02431260
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
NCT02393248
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
NCT02298153
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
NCT02318277
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
NCT02327078
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
NCT02257619
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
NCT02265510
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
NCT02252159
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
NCT02178722
A Study of Ruxolitinib in Pancreatic Cancer Patients
NCT02119663
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
NCT02120417
INCB047986 in Rheumatoid Arthritis
NCT02151474
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 100 |
| Phase 2 | 83 |
| Phase 3 | 49 |
| Phase 4 | 1 |
What is open in the Incyte Corporation pipeline
37 recruiting of 239 indexed (15% open); 126 completed (53%).
Phase mix: 50 late (III/IV) vs 183 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Incyte Corporation: open-pipeline peers nationwide
Peers matched on 239 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Incyte Corporation sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 239 trials (± recruiting share)
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
- Loma Linda University · 237 trials · 15% recruiting
- Daiichi Sankyo · 236 trials · 12% recruiting
- State University of New York at Buffalo · 243 trials · 21% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Brigham and Women's Hospital · 15% recruiting · 937 trials
- Northwestern University · 15% recruiting · 1,209 trials
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- University of Michigan Rogel Cancer Center · 15% recruiting · 292 trials
Related
What to do with this Incyte Corporation page
239 registered trials is a research-attention snapshot, not an endorsement of Incyte Corporation or any single study.
- 37 of Incyte Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Solid Tumors is the condition Incyte Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Incyte Corporation pipeline card: 239 registered trials from official public datasets.Report a data error.